Blood test could spot pancreatic cancer before It's visible

NCT ID NCT02471170

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study collects blood samples from people with pancreatic diseases to look for markers that might signal pancreatic cancer. The goal is to see if a blood test could detect the cancer earlier than current methods or help track how the disease changes during treatment. Samples will also be stored in a biobank for future research. Participants include patients being evaluated or treated for pancreatic disease, as well as control patients without pancreatic disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test that detects pancreatic cancer earlier or helps doctors monitor the disease during treatment.
What could go wrong: This is an observational study, not a treatment trial. It may not find reliable markers, and any potential test would require much larger studies to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreas disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DISEASES

Contacts and locations

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.